Tirzepatide 20mg
Dual GIP/GLP-1 receptor agonist — high-dose vial for maintenance and advanced protocols.
Tap a strength to switch — price, image & stock update automatically
Key Benefits
10–15 mg/week doses produce full GIP + GLP-1 receptor engagement for peak metabolic response
22.5% mean body weight loss at 15 mg in SURMOUNT-1, outperforming all other approved weight-loss compounds
SURMOUNT-4 shows weight loss is maintained with continued dosing; discontinuation leads to significant regain
reduces visceral adiposity, improves lipid profiles, and lowers blood pressure at maintenance doses
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
Tirzepatide is a 39-amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid chain enabling albumin binding and a ~5-day half-life. At maintenance doses (10–15 mg/week), the dual receptor mechanism produces maximal activation of both incretin pathways — GIP receptor agonism enhances insulin secretion and directly signals adipocytes, while GLP-1 receptor agonism suppresses appetite via hypothalamic pathways and delays gastric emptying.
Research Highlights
- SURMOUNT-1: 22.5% mean body weight reduction at 15 mg/week over 72 weeks — highest of any approved weight-loss drug
- SURMOUNT-4: participants who continued tirzepatide after 36-week run-in maintained 5.5% additional weight loss vs 14% regain in placebo group
- SURPASS-CVOT: ongoing cardiovascular outcomes trial; interim data shows favorable cardiometabolic profile
- Phase 3 SURMOUNT-MMO trial: evaluating cardiovascular mortality benefit in obese patients without T2D
Randomised controlled trial data available. Results are compound-specific and do not constitute treatment guidance.
For laboratory research only
All Research Systems →For research use only — not for human consumption. No treatment claims.
Full Research Hub →How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 20mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Tirzepatide is a 39-amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid chain enabling albumin binding and a ~5-day half-life. At maintenance doses (10–15 mg/week), the dual receptor mechanism produces maximal activation of both incretin pathways — GIP receptor agonism enhances insulin secretion and directly signals adipocytes, while GLP-1 receptor agonism suppresses appetite via hypothalamic pathways and delays gastric emptying.
Clinical Context
The 20mg vial is designed for researchers working with maintenance-phase protocols (10–15 mg/week). At these doses, tirzepatide demonstrates its full dual-mechanism efficacy. The SURMOUNT program is the largest obesity trial program ever conducted, with over 15,000 participants across multiple Phase 3 trials. FDA approved as Zepbound for chronic weight management in 2023.
Research Highlights
- SURMOUNT-1: 22.5% mean body weight reduction at 15 mg/week over 72 weeks — highest of any approved weight-loss drug
- SURMOUNT-4: participants who continued tirzepatide after 36-week run-in maintained 5.5% additional weight loss vs 14% regain in placebo group
- SURPASS-CVOT: ongoing cardiovascular outcomes trial; interim data shows favorable cardiometabolic profile
- Phase 3 SURMOUNT-MMO trial: evaluating cardiovascular mortality benefit in obese patients without T2D
Storage & Reconstitution
Key Studies
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM et al.
Tirzepatide 15 mg/week produced 22.5% mean body weight reduction at 72 weeks — highest of any approved weight-loss drug.
PubMed →Tirzepatide maintenance of weight loss (SURMOUNT-4)
Aronne LJ et al.
Continued tirzepatide maintained 5.5% additional weight loss vs 14% regain in placebo — confirming need for continued therapy.
PubMed →Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías JP et al.
Tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1 mg — superior glycemic control.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Appetite suppression, insulin secretion, gastric emptying delay
Enhanced insulin secretion, adipocyte lipolysis — dual mechanism superior to GLP-1 alone
Maximum dual-receptor satiety signaling at maintenance doses
Direct lipolysis and fat cell metabolism regulation
Side Effects & Adverse Events
- Nausea (33%)
- Diarrhea (23%)
- Vomiting (18%)
- Constipation (17%)
- Injection site reactions
- Decreased appetite
- Fatigue
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (rodent data)
Contraindications & Interactions
Synergistic Compounds
Lipo-C provides B12 repletion and lipotropic support during maintenance-phase caloric restriction.
Lipo-C 1 mL IM 2–3× per week alongside weekly tirzepatide maintenance injection.
View Compound →Adding amylin receptor agonism to dual GIP/GLP-1 agonism for maximum weight loss outcomes.
Tirzepatide 10–15 mg + Cagrilintide 2.4 mg, both once weekly SubQ.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States